Browse by People

Up a level
Export as [feed] RSS [feed] RSS 2.0 Short Author List
Number of items: 6.

Rose-Zerilli, Matthew John Jerome, Parker, Helen, Larrayoz, Marta, Clifford, Ruth, Blakemore, Stuart, Edelmann, Jennifer, Gibson, Jane, Wang, Jun, Ljungstrom, Viktor, Chaplin, Tracy
et al (show 26 more authors) (2015) Genomic Disruption of the Histone Methyltransferase SETD2 in Chronic Lymphocytic Leukemia. .

Schuh, Anna H, Parry-Jones, Nilima, Appleby, Niamh, Bloor, Adrian, Dearden, Claire E, Fegan, Christopher, Follows, George, Fox, Christopher P, Iyengar, Sunil, Kennedy, Ben
et al (show 7 more authors) (2018) Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology Guideline. BRITISH JOURNAL OF HAEMATOLOGY, 182 (3). 344 - 359.

Hillmen, Peter, Rawstron, Andy C, Brock, Kristian ORCID: 0000-0002-3921-0166, Muñoz-Vicente, Samuel, Yates, Francesca J, Bishop, Rebecca, Boucher, Rebecca, MacDonald, Donald, Fegan, Christopher, McCaig, Alison
et al (show 9 more authors) (2019) Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 37 (30). 2722 - 2729.

Eagle, Gina, Zhuang, Jack ORCID: 0000-0003-3245-0789, Oates, Melanie, Kitteringham, Neil, Herbert, John, Falciani, Francesco, Pettitt, Andrew, Park, Kevin, Jenkins, Rosalind, Devereux, Stephen
et al (show 2 more authors) (2017) Linking genotype to clinical phenotype through proteomic analysis of CLL trial samples. .

Alharthi, Afaf, Beck, Daniel, Howard, Dena R, Hillmen, Peter, Oates, Melanie, Pettitt, Andrew and Wagner, Simon D ORCID: 0000-0002-8914-0370
(2018) An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects. BMC research notes, 11 (1). 280 - ?.

Pratt, Guy, Yap, Christina, Oldreive, Ceri, Slade, Daniel, Bishop, Rebecca, Griffiths, Mike, Dyer, Martin JS, Fegan, Chris, Oscier, David, Pettitt, Andrew
et al (show 9 more authors) (2018) A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma. BRITISH JOURNAL OF HAEMATOLOGY, 182 (3). 429 - 433.

This list was generated on Sun Nov 10 19:56:26 2019 GMT.